This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Will Higher Medicare Revenues Aid Aetna (AET) Q1 Earnings?
by Zacks Equity Research
Aetna (AET) Q1 earnings should benefit from growth in its Medicare business and a lower tax rate, partly offset by a decline in revenues.
Why Earnings Season Could Be Great for Aetna (AET)
by Zacks Equity Research
Aetna (AET) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Tenet Healthcare's (THC) Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Tenet Healthcare's (THC) earnings are likely to beat estimates in the first quarter, riding high on the robust performance of its Ambulatory segment.
Anthem (ANTM) Q1 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Anthem's (ANTM) first-quarter earnings might gain from a solid Government business. However, persistent softness in Individual business is likely to affect overall results.
UnitedHealth (UNH) Q1 Earnings to Gain From Optum Revenues
by Zacks Equity Research
UnitedHealth (UNH) Q1 earnings should see an upside from higher revenues in its health services segment named Optum.
Humana (HUM) Shores Up Government Business With FPG Buyout
by Zacks Equity Research
Humana's (HUM) Medicare business is expected to benefit from its strategic acquisitions.
Check These 3 Health Insurers to Reap High Returns in Q2
by Zacks Equity Research
We streamline our search to three best insurance bets with potential to turn investors rich by garnering fat returns.
Medicare Rate Up More than Expected, Health Insurers to Gain
by Zacks Equity Research
Increase in Medicare Advantage reimburse rates bodes well for health insurers.
Are Options Traders Betting on a Big Move in Aetna (AET) Stock?
by Zacks Equity Research
Investors in Aetna (AET) need to pay close attention to the stock based on moves in the options market lately.
Rite Aid-Albertsons Merger Crosses First Antitrust Hurdle
by Zacks Equity Research
Rite Aid (RAD) successfully crosses the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, taking its first step toward merger with Albertsons.
Can Walmart Fortify Position Against Amazon With Humana Deal?
by Zacks Equity Research
Walmart's (WMT) plans to extend existing ties with Humana to enhance healthcare offerings, seems another bullet shot by the former in its war against the e-commerce king.
Should Value Investors Consider Aetna (AET) Stock Right Now?
by Zacks Equity Research
Is Aetna (AET) a great pick from the value investor's perspective right now? Read on to know more.
Centene Makes Investment in RxAdvance, Builds Partnership
by Zacks Equity Research
Centene's (CNC) transformative alliance with RxAdvance is another instance of Health insurers joining forces with pharmacy benefit managers to reduce the costs in the drug supply chain.
Cigna, Express Script Deal to Continue Healthcare Reshuffle
by Zacks Equity Research
Cigna's (CI) acquisition of Express Scripts should transform it into a more diversified entity.
Teladoc (TDOC) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Teladoc (TDOC) earnings were aided by membership growth and increased visits.
Envision Healthcare (EVHC) Q4 Earnings Beat, Revenues Rise
by Zacks Equity Research
Envision Healthcare (EVHC) earnings benefited from higher revenues partly offset by an increase in expenses.
Tenet Healthcare (THC) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
Strong segmental performances along with solid expense management aid Tenet Healthcare's (THC) Q4.
Select Medical (SEM) Q4 Earnings Top Estimates, Keeps View
by Zacks Equity Research
Solid segmental performances aid Select Medical's (SEM) Q4 earnings.
Walgreens (WBA) May Buy Remaining Stake in AmerisourceBergen
by Zacks Equity Research
Walgreens' (WBA) rumored buyout claim over the remaining stake in AmerisourceBergen comes close on the heels of its rival CVS Health's hefty $69-billion worth acquisition of health insurer, Aetna.
Molina Healthcare (MOH) Tops on Q4 Earnings, Issues '18 View
by Zacks Equity Research
Restructuring costs and impairment loss affect Molina Healthcare's (MOH) fourth-quarter results.
Can Solid Retail Segment Drive Humana's (HUM) Q4 Earnings?
by Zacks Equity Research
Humana's (HUM) fourth-quarter results are likely to gain from solid premium growth, especially in the Retail segment.
Cigna Q4 Earnings Top on Higher Enrollment, 2018 View Issued
by Zacks Equity Research
Cigna (CI) Q4 earnings grow on higher revenues, which gained from higher premium and fees and increase in membership.
Company News For Jan 31, 2018
by Zacks Equity Research
Companies In The News are: AET,MXIM,AXE,SMG
Aetna (AET) Q4 Earnings Top Estimates, Enrollment Declines
by Zacks Equity Research
Aetna (AET) results suffered from lower enrollment, investment spending and favorable development of prior-year health cost.
Q4 Results Remain Positive, Market Dips
by Zacks Equity Research
Q4 Results Remain Positive, Market Dips